Regeneron's 2025 outlook includes defensive capital allocation, competitive pressure on Eylea, et cetera. Click here to read ...

Regeneron Pharmaceuticals Inc (REGN) reports robust financial performance with a 10% revenue increase and unveils new ...

Q4 2024 Earnings Call Transcript February 4, 2025 Operator: Hello, and welcome to Regeneron Pharmaceuticals Fourth Quarter 2024 Earnings Conference Call. My name is Tawanda, and I will be your ...

Precision medicine is revolutionizing healthcare, and these genomic stocks are leading the way. Therefore, as this sector ...

Regeneron's CD20xCD3 bispecific antibody for non-Hodgin lymphoma (NHL) has been approved in Europe, five months after it was turned down by the FDA in the US. Ordspono (odronextamab) has been ...

Biotech giant Regeneron Pharmaceuticals, Inc. REGN is slated to report fourth-quarter and full-year 2024 results on Feb. 4, ...

but the safety and efficacy of odronextamab has not been fully evaluated by any other regulatory authority. Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents, develops and ...

but the safety and efficacy of odronextamab has not been fully evaluated by any other regulatory authority. Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents, develops and ...

Regeneron recently announced that the primary ... REGN’s oncology franchise got a boost with the European Commission's approval of odronextamab for treating adult patients with relapsed or ...

The FDA has turned down a pair of marketing applications for Regeneron’s CD20xCD3 bispecific antibody odronextamab to treat two common forms of non-Hodgkin lymphoma (NHL). The decision throws a ...

Odronextamab is under clinical development by Regeneron Pharmaceuticals and currently in Phase III for B-Cell Non-Hodgkin Lymphoma. According to GlobalData, Phase III drugs for B-Cell Non-Hodgkin ...

Odronextamab is under clinical development by Regeneron Pharmaceuticals and currently in Phase II for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia). According to GlobalData, Phase II ...